A team of academics of the Colombo University Faculties of Science and Medicine received the first US Patent for their discovery of a compound that shows significant anti-cancer activities.
The team from UOC has discovered a compound extracted from the mushroom Fulviformes fastuosus to show significant anticancer activity against Rhabdomyosarcoma, which is an aggressive and highly malignant form of childhood cancer.
A patent-right is a form of intellectual property that gives its owner the legal right to exclude others from making, using, selling and importing an invention for a limited period of years.
According to UOC the invention is pertinent to “A novel method to isolate a potent anticancer compound inoscavin A from a Sri Lankan terrestrial mushroom, Fulviformes fastuosus, to treat rhabdomyosarcoma cancer”.
This novel method can be effectively used for the preparation of any antitumor medicinal preparation using inoscavin A.
The uniqueness of this compound, Inoscavin A, is that:
- It is active at nanogram levels where the control drug was active at mg levels
- Non-detectable toxicity to normal cells
The teams’ future plan is to embark on new areas of Biotechnology research based on natural product and anticancer research that are relevant to the development of the industrial base in Sri Lanka within an internationally competitive landscape.
Source – CMB